326(top 1%)
PR articles
14.7K(top 1%)
PR citations
56(top 1%)
PR h-index
64(top 1%)
h-index
378
documents
20.0K
doc citations
2.4K
citing journals
100
times ranked

Publications

333 PR articles • 15,783 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant
Science Advances, 2025, 11,
10.912Citations (PDF)
2Modulation of germinal center and antibody dynamics via ipsilateral versus contralateral immunization against SARS-CoV-2
Journal of Immunology, 2025, 214, 335-346
0.61Citations (PDF)
3Fc Functions and Anti-HIV Neutralizing Antibodies: A Perspective
Current HIV Research, 2025, 23, 353-356
0.90Citations (PDF)
4Deconvoluting TCR-dependent and -independent activation is vital for reliable Ag-specific CD4 + T cell characterization by AIM assay
Science Advances, 2025, 11,
10.912Citations (PDF)
5γδ T cells mediate robust anti‐HIV functions during antiretroviral therapy regardless of immune checkpoint expression
Clinical and Translational Immunology, 2024, 13,
3.64Citations (PDF)
6Immunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagents
Clinical and Translational Immunology, 2024, 13,
3.67Citations (PDF)
7Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
Lancet Microbe, The, 2024, 5, e459-e467
12.322Citations (PDF)
8Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection
Nature Communications, 2024, 15,
13.730Citations (PDF)
9Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin
Nature Microbiology, 2024, 9, 2073-2083
16.016Citations (PDF)
10SARS-CoV-2-specific CD8 + T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years
Proceedings of the National Academy of Sciences of the United States of America, 2024, 121,
7.513Citations (PDF)
11Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans
ACS Nano, 2024, 18, 27077-27089
15.338Citations (PDF)
12Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates
Nature Communications, 2024, 15,
13.712Citations (PDF)
13Patient-Specific Nanoparticle Targeting in Human Leukemia Blood
ACS Nano, 2024, 18, 29021-29035
15.325Citations (PDF)
14Transiently boosting Vγ9+Vδ2+ γδ T cells early in Mtb coinfection of SIV-infected juvenile macaques does not improve Mtb host resistance
Infection and Immunity, 2024, 92,
2.71Citations (PDF)
15Circulating effector γδ T cell populations are associated with acute coronavirus disease 19 in unvaccinated individuals
Immunology and Cell Biology, 2023, 101, 321-332
2.610Citations (PDF)
16Host Immunity to Mycobacterium tuberculosis Infection Is Similar in Simian Immunodeficiency Virus (SIV)-Infected, Antiretroviral Therapy-Treated and SIV-Naïve Juvenile Macaques
Infection and Immunity, 2023, 91,
2.75Citations (PDF)
17Predicting the efficacy of variant-modified COVID-19 vaccine boosters
Nature Medicine, 2023, 29, 574-578
33.078Citations (PDF)
18Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Nature Communications, 2023, 14,
13.7107Citations (PDF)
19Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
EBioMedicine, 2023, 92, 104574
9.713Citations (PDF)
20Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
JCI Insight, 2023, 8,
5.45Citations (PDF)
21Robust immunity to influenza vaccination in haematopoietic stem cell transplant recipients following reconstitution of humoral and adaptive immunity
Clinical and Translational Immunology, 2023, 12,
3.66Citations (PDF)
22Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
Science Advances, 2023, 9,
10.924Citations (PDF)
23Monoclonal antibody levels and protection from COVID-19
Nature Communications, 2023, 14,
13.743Citations (PDF)
24Broad spectrum SARS‐CoV‐2‐specific immunity in hospitalized First Nations peoples recovering from COVID‐19
Immunology and Cell Biology, 2023, 101, 964-974
2.62Citations (PDF)
25Mucosal antibody responses following Vaxzevria vaccination
Immunology and Cell Biology, 2023, 101, 975-983
2.67Citations (PDF)
26Antibody glycosylation correlates with disease progression in SIV‐Mycobacterium tuberculosis coinfected cynomolgus macaques
Clinical and Translational Immunology, 2023, 12,
3.66Citations (PDF)
27Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
EBioMedicine, 2023, 98, 104878
9.715Citations (PDF)
28Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence
Immunology and Cell Biology, 2022, 100, 49-60
2.615Citations (PDF)
29T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination
Journal of Leukocyte Biology, 2022, 111, 355-365
2.934Citations (PDF)
30Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Lancet Microbe, The, 2022, 3, e52-e61
12.3579Citations (PDF)
31Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
Nature Immunology, 2022, 23, 210-216
23.6836Citations (PDF)
32Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles
Science Immunology, 2022, 7,
13.485Citations (PDF)
33A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination
Frontiers in Immunology, 2022, 13,
4.96Citations (PDF)
34Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory
Nature Immunology, 2022, 23, 768-780
23.661Citations (PDF)
35At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
Frontiers in Immunology, 2022, 13,
4.914Citations (PDF)
36Protein precoating modulates biomolecular coronas and nanocapsule–immune cell interactions in human blood
Journal of Materials Chemistry B, 2022, 10, 7607-7621
5.527Citations (PDF)
37Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine
ACS Nano, 2022, 16, 11769-11780
15.3294Citations (PDF)
38Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Frontiers in Immunology, 2022, 13,
4.912Citations (PDF)
39Heterologous SARS‐CoV ‐2 IgA neutralising antibody responses in convalescent plasma
Clinical and Translational Immunology, 2022, 11,
3.69Citations (PDF)
40Immune profiling of influenza‐specific B‐ and T‐cell responses in macaques using flow cytometry‐based assays
Immunology and Cell Biology, 2021, 99, 97-106
2.68Citations (PDF)
41CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection
International Journal of Molecular Sciences, 2021, 22, 912
4.47Citations (PDF)
42Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
Clinical and Translational Immunology, 2021, 10,
3.629Citations (PDF)
43Antibody mediated activation of natural killer cells in malaria exposed pregnant women
Scientific Reports, 2021, 11,
3.414Citations (PDF)
44Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Nature Communications, 2021, 12,
13.7356Citations (PDF)
45Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans
Cell Reports, 2021, 34, 108684
6.3209Citations (PDF)
46Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity
Advanced Healthcare Materials, 2021, 10,
8.834Citations (PDF)
47Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
Cell Reports Medicine, 2021, 2, 100208
6.6150Citations (PDF)
48Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Nature Communications, 2021, 12,
13.779Citations (PDF)
49Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Proceedings of the National Academy of Sciences of the United States of America, 2021, 118,
7.5142Citations (PDF)
50Systems serology detects functionally distinct coronavirus antibody features in children and elderly
Nature Communications, 2021, 12,
13.7162Citations (PDF)
51Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients
Nature Communications, 2021, 12,
13.756Citations (PDF)
52CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
Immunity, 2021, 54, 1066-1082.e5
22.6136Citations (PDF)
53Influence of Poly(ethylene glycol) Molecular Architecture on Particle Assembly and Ex Vivo Particle–Immune Cell Interactions in Human Blood
ACS Nano, 2021, 15, 10025-10038
15.342Citations (PDF)
54Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Nature Medicine, 2021, 27, 1205-1211
33.03,786Citations (PDF)
55Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Cell Reports Medicine, 2021, 2, 100296
6.677Citations (PDF)
56SARS‐CoV‐2‐specific CD8+ T‐cell responses and TCR signatures in the context of a prominent HLA‐A*24:02 allomorph
Immunology and Cell Biology, 2021, 99, 990-1000
2.640Citations (PDF)
57Quantitatively Tracking Bio–Nano Interactions of Metal–Phenolic Nanocapsules by Mass Cytometry
ACS Applied Materials & Interfaces, 2021, 13, 35494-35505
8.012Citations (PDF)
58Interactions of core cross-linked poly(2-oxazoline) and poly(2-oxazine) micelles with immune cells in human blood
Biomaterials, 2021, 274, 120843
12.141Citations (PDF)
59Plasma Corona Protects Human Immune Cells from Structurally Nanoengineered Antimicrobial Peptide Polymers
ACS Applied Materials & Interfaces, 2021, 13, 33821-33829
8.05Citations (PDF)
60Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
JCI Insight, 2021, 6,
5.442Citations (PDF)
61Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure
EBioMedicine, 2021, 70, 103518
9.75Citations (PDF)
62From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Acta Biomaterialia, 2021, 131, 16-40
9.3231Citations (PDF)
63Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein
Journal of Biological Chemistry, 2021, 297, 101065
2.241Citations (PDF)
64A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
Cell Reports Medicine, 2021, 2, 100386
6.615Citations (PDF)
65Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Cell Reports, 2021, 37, 109822
6.351Citations (PDF)
66Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences
European Respiratory Journal, 2021, 57, 2003730
8.7129Citations (PDF)
67Adaptive immunity to human coronaviruses is widespread but low in magnitude
Clinical and Translational Immunology, 2021, 10,
3.621Citations (PDF)
68Stealth nanorods via the aqueous living crystallisation-driven self-assembly of poly(2-oxazoline)s
Chemical Science, 2021, 12, 7350-7360
7.150Citations (PDF)
69Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells
Scientific Reports, 2021, 11,
3.45Citations (PDF)
70Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians
Proceedings of the National Academy of Sciences of the United States of America, 2021, 118,
7.56Citations (PDF)
71Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
Frontiers in Immunology, 2021, 12,
4.96Citations (PDF)
72Current and future nanoparticle vaccines for COVID-19
EBioMedicine, 2021, 74, 103699
9.782Citations (PDF)
73A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2
EBioMedicine, 2021, 74, 103729
9.740Citations (PDF)
74Tear antibodies to SARS‐CoV‐2: implications for transmission
Clinical and Translational Immunology, 2021, 10,
3.616Citations (PDF)
75Serological and cellular inflammatory signatures in end‐stage kidney disease and latent tuberculosis
Clinical and Translational Immunology, 2021, 10,
3.69Citations (PDF)
76Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
Science, 2020, 367,
36.2403Citations (PDF)
77The protective potential of Fc‐mediated antibody functions against influenza virus and other viral pathogens
Immunology and Cell Biology, 2020, 98, 253-263
2.656Citations (PDF)
78Serum IgA Fc effector functions in infectious disease and cancer
Immunology and Cell Biology, 2020, 98, 276-286
2.662Citations (PDF)
79Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Nature Medicine, 2020, 26, 1428-1434
33.0448Citations (PDF)
80Template‐Mediated Assembly of DNA into Microcapsules for Immunological Modulation
Small, 2020, 16,
11.534Citations (PDF)
81Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
Nature Reviews Immunology, 2020, 20, 727-738
53.8124Citations (PDF)
82Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood
ACS Nano, 2020, 14, 15723-15737
15.3107Citations (PDF)
83Understanding the Role of Mucosal-Associated Invariant T-Cells in Non-human Primate Models of HIV Infection
Frontiers in Immunology, 2020, 11,
4.96Citations (PDF)
84Block and Lock HIV Cure Strategies to Control the Latent Reservoir
Frontiers in Cellular and Infection Microbiology, 2020, 10,
4.158Citations (PDF)
85Controlling the Biological Fate of Micellar Nanoparticles: Balancing Stealth and Targeting
ACS Nano, 2020, 14, 13739-13753
15.341Citations (PDF)
86Suboptimal SARS-CoV-2−specific CD8 + T cell response associated with the prominent HLA-A*02:01 phenotype
Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391
7.5195Citations (PDF)
87Modulating the Selectivity and Stealth Properties of Ellipsoidal Polymersomes through a Multivalent Peptide Ligand Display
Advanced Healthcare Materials, 2020, 9,
8.813Citations (PDF)
88What Can Gamma Delta T Cells Contribute to an HIV Cure?
Frontiers in Cellular and Infection Microbiology, 2020, 10,
4.124Citations (PDF)
89Sequencing B cell receptors from ferrets (Mustela putorius furo)
PLoS ONE, 2020, 15, e0233794
2.313Citations (PDF)
90High CD26 and Low CD94 Expression Identifies an IL-23 Responsive Vδ2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile
Cell Reports, 2020, 31, 107773
6.343Citations (PDF)
91Innate and Adaptive Anti-SIV Responses in Macaque Semen: Implications for Infectivity and Risk of Transmission
Frontiers in Immunology, 2020, 11,
4.98Citations (PDF)
92Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network
Small, 2020, 16,
11.580Citations (PDF)
93Meibomian gland dropout is associated with immunodeficiency at HIV diagnosis: Implications for dry eye disease
Ocular Surface, 2020, 18, 206-213
4.215Citations (PDF)
94Low‐Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking
Angewandte Chemie, 2020, 132, 4759-4765
1.431Citations (PDF)
95Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults
Vaccine, 2020, 38, 2368-2377
3.110Citations (PDF)
96Low‐Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking
Angewandte Chemie - International Edition, 2020, 59, 4729-4735
14.460Citations (PDF)
97Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques
Scientific Reports, 2020, 10,
3.47Citations (PDF)
98Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation
JCI Insight, 2020, 5,
5.4105Citations (PDF)
99Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem
PLoS ONE, 2020, 15, e0241649
2.32Citations (PDF)
100Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes
AIDS Research and Human Retroviruses, 2019, 35, 553-556
1.44Citations (PDF)
101Boosting of Markers of Fcγ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption
AIDS Research and Human Retroviruses, 2019, 35, 842-852
1.41Citations (PDF)
102Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid
Biomacromolecules, 2019, 20, 4208-4217
5.118Citations (PDF)
103Impact of HIV‐1 viremia or sexually transmitted infection on semen‐derived anti‐HIV‐1 antibodies and the immunosuppressive capacity of seminal plasma
European Journal of Immunology, 2019, 49, 2255-2258
3.21Citations (PDF)
104Improving immunological insights into the ferret model of human viral infectious disease
Influenza and Other Respiratory Viruses, 2019, 13, 535-546
3.437Citations (PDF)
105Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and <i>Candida albicans</i>
ACS Applied Materials &amp; Interfaces, 2019, 11, 34676-34687
8.015Citations (PDF)
106Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
Nature Communications, 2019, 10,
13.787Citations (PDF)
107A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface
Cell, 2019, 177, 1136-1152.e18
33.7243Citations (PDF)
108Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques
Scientific Reports, 2019, 9,
3.415Citations (PDF)
109Link between Low-Fouling and Stealth: A Whole Blood Biomolecular Corona and Cellular Association Analysis on Nanoengineered Particles
ACS Nano, 2019, 13, 4980-4991
15.361Citations (PDF)
110Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1
Frontiers in Immunology, 2019, 10,
4.946Citations (PDF)
111Inducible Bronchus-Associated Lymphoid Tissues (iBALT) Serve as Sites of B Cell Selection and Maturation Following Influenza Infection in Mice
Frontiers in Immunology, 2019, 10,
4.970Citations (PDF)
112Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of <i>In Vitro</i> versus <i>In Vivo</i> Models
Journal of Virology, 2019, 93,
3.63Citations (PDF)
113CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity
Journal of Virology, 2019, 93,
3.613Citations (PDF)
114Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies
Advanced Healthcare Materials, 2019, 8,
8.847Citations (PDF)
115Role of IgG3 in Infectious Diseases
Trends in Immunology, 2019, 40, 197-211
10.5197Citations (PDF)
116Identification of murine antigen-specific T follicular helper cells using an activation-induced marker assay
Journal of Immunological Methods, 2019, 467, 48-57
1.420Citations (PDF)
117Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection
Current Opinion in HIV and AIDS, 2019, 14, 77-84
3.329Citations (PDF)
118Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions
Frontiers in Immunology, 2019, 10,
4.947Citations (PDF)
119An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
Frontiers in Immunology, 2019, 10,
4.929Citations (PDF)
120Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways
Journal of Virology, 2019, 93,
3.644Citations (PDF)
121Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells
Journal of Virology, 2019, 93,
3.654Citations (PDF)
122Immunological basis for enhanced immunity of nanoparticle vaccines
Expert Review of Vaccines, 2019, 18, 269-280
4.0126Citations (PDF)
123Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques
Journal of Clinical Investigation, 2019, 129, 182-191
10.681Citations (PDF)
124Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem
Journal of Clinical Investigation, 2019, 129, 850-862
10.697Citations (PDF)
125Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions
Journal of Virology, 2018, 92,
3.617Citations (PDF)
126Human plasma proteome association and cytotoxicity of nano-graphene oxide grafted with stealth polyethylene glycol and poly(2-ethyl-2-oxazoline)
Nanoscale, 2018, 10, 10863-10875
5.054Citations (PDF)
127The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial
Lancet HIV,the, 2018, 5, e221-e230
7.946Citations (PDF)
128Circulating T FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity
Science Translational Medicine, 2018, 10,
12.5222Citations (PDF)
129Identification of Native and Posttranslationally Modified HLA‐B*57:01‐Restricted HIV Envelope Derived Epitopes Using Immunoproteomics
Proteomics, 2018, 18,
3.126Citations (PDF)
1302017 international meeting of the Global Virus Network
Antiviral Research, 2018, 153, 60-69
3.83Citations (PDF)
131Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults
Journal of Infectious Diseases, 2018, 217, 12-23
3.840Citations (PDF)
132A Lipid/DNA Adjuvant–Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge
Journal of Infectious Diseases, 2018, 218, 856-867
3.813Citations (PDF)
133Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC
Journal of Immunological Methods, 2018, 457, 41-52
1.455Citations (PDF)
134Anti-HIV-1 antibody-dependent cellular cytotoxicity
Current Opinion in HIV and AIDS, 2018, 13, 160-166
3.328Citations (PDF)
135Ageing in patients with chronic HIV infection: impact of hypercoagulation
AIDS Research and Therapy, 2018, 15,
2.15Citations (PDF)
136Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial
Lancet HIV,the, 2018, 5, e553-e559
7.921Citations (PDF)
137The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1
Frontiers in Immunology, 2018, 9,
4.97Citations (PDF)
138Influence of Charge on Hemocompatibility and Immunoreactivity of Polymeric Nanoparticles
ACS Applied Bio Materials, 2018, 1, 756-767
4.733Citations (PDF)
139Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating Factor Production During End-Stage Renal Disease
Frontiers in Immunology, 2018, 9,
4.918Citations (PDF)
140Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection
Viruses, 2018, 10, 333
3.28Citations (PDF)
141A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA
Nature Communications, 2018, 9,
13.796Citations (PDF)
142Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine
Human Gene Therapy, 2018, 29, 1011-1028
3.210Citations (PDF)
143The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV
AIDS Research and Human Retroviruses, 2018, 34, 727-738
1.422Citations (PDF)
144Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies
Retrovirology, 2018, 15,
3.543Citations (PDF)
145Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection
Journal of Infectious Diseases, 2018, 218, 1383-1393
3.810Citations (PDF)
146Functional cure of HIV: the scale of the challenge
Nature Reviews Immunology, 2018, 19, 45-54
53.8117Citations (PDF)
147Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery
ACS Nano, 2017, 11, 54-68
15.3181Citations (PDF)
148Antibody-dependent cellular cytotoxicity and influenza virus
Current Opinion in Virology, 2017, 22, 89-96
5.071Citations (PDF)
149Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents
Journal of Virology, 2017, 91,
3.622Citations (PDF)
150Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood
ACS Macro Letters, 2017, 6, 586-592
5.031Citations (PDF)
151Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome
Aids, 2017, 31, 1839-1845
2.512Citations (PDF)
152Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
EBioMedicine, 2017, 19, 119-127
9.735Citations (PDF)
153Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components
ACS Applied Materials &amp; Interfaces, 2017, 9, 12182-12194
8.027Citations (PDF)
154Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts
Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 345-353
1.713Citations (PDF)
155Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution
ACS Applied Materials &amp; Interfaces, 2017, 9, 33683-33694
8.021Citations (PDF)
156Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV
Human Vaccines and Immunotherapeutics, 2017, 13, 2726-2737
3.11Citations (PDF)
157Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?
Journal of Virology, 2017, 91,
3.611Citations (PDF)
158Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults
Vaccine, 2017, 35, 6451-6458
3.118Citations (PDF)
159Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
Science Translational Medicine, 2017, 9,
12.550Citations (PDF)
16013 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption
Journal of Virus Eradication, 2017, 3, 10
0.40Citations (PDF)
161Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein
Frontiers in Immunology, 2017, 8,
4.924Citations (PDF)
162Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?
Frontiers in Immunology, 2017, 8,
4.9200Citations (PDF)
163HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells
Frontiers in Immunology, 2017, 8,
4.931Citations (PDF)
164Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection
Frontiers in Immunology, 2017, 8,
4.911Citations (PDF)
165A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
Frontiers in Immunology, 2017, 8,
4.925Citations (PDF)
166Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
Frontiers in Immunology, 2017, 8,
4.917Citations (PDF)
167Fc functional antibodies in humans with severe H7N9 and seasonal influenza
JCI Insight, 2017, 2,
5.446Citations (PDF)
168Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field
Current HIV Research, 2017, 15,
0.929Citations (PDF)
169Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime–boost immunization
Mucosal Immunology, 2017, 11, 994-1007
7.050Citations (PDF)
170Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma
Aids, 2017, 31, 333-342
2.515Citations (PDF)
171Brief Report
Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 17-23
1.718Citations (PDF)
172Influenza-Specific Antibody-Dependent Phagocytosis
PLoS ONE, 2016, 11, e0154461
2.355Citations (PDF)
173Functional advantage of educated KIR2DL1+ natural killer cells for anti-HIV-1 antibody-dependent activation
Clinical and Experimental Immunology, 2016, 184, 101-109
3.418Citations (PDF)
174HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation
Scientific Reports, 2016, 6,
3.436Citations (PDF)
175Human immune cell targeting of protein nanoparticles – caveospheres
Nanoscale, 2016, 8, 8255-8265
5.033Citations (PDF)
176Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine
Journal of Virology, 2016, 90, 5724-5734
3.655Citations (PDF)
177Cutaneous mucormycosis secondary to penetrative trauma
Injury, 2016, 47, 1383-1387
1.720Citations (PDF)
178NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity
AIDS Research and Human Retroviruses, 2016, 32, 1089-1096
1.435Citations (PDF)
179The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype
Vaccine, 2016, 34, 5251-5261
3.136Citations (PDF)
180Tuning the properties of pH responsive nanoparticles to control cellular interactions in vitro and ex vivo
Polymer Chemistry, 2016, 7, 6015-6024
3.920Citations (PDF)
181HIV vaccines moving forward
Current Opinion in HIV and AIDS, 2016, 11, 545
3.30Citations (PDF)
182What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins
EBioMedicine, 2016, 8, 277-290
9.777Citations (PDF)
183Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination
Expert Review of Vaccines, 2016, 15, 719-729
4.032Citations (PDF)
184Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control
Journal of NeuroVirology, 2016, 22, 498-507
1.611Citations (PDF)
185Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses
Vaccine, 2016, 34, 1172-1179
3.116Citations (PDF)
186High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo
Virology, 2016, 492, 1-10
2.311Citations (PDF)
187Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells
Journal of Virology, 2016, 90, 2021-2030
3.658Citations (PDF)
188HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
PLoS Pathogens, 2015, 11, e1005000
4.4108Citations (PDF)
189MAIT cells are depleted early but retain functional cytokine expression in HIV infection
Immunology and Cell Biology, 2015, 93, 177-188
2.695Citations (PDF)
190Engineering Poly(ethylene glycol) Particles for Improved Biodistribution
ACS Nano, 2015, 9, 1571-1580
15.3171Citations (PDF)
191Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis
Journal of Leukocyte Biology, 2015, 97, 599-609
2.915Citations (PDF)
192Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non‐human primates
European Journal of Immunology, 2015, 45, 854-864
3.284Citations (PDF)
193Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity
Expert Review of Vaccines, 2015, 14, 1227-1239
4.018Citations (PDF)
194Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation
Clinical and Experimental Immunology, 2015, 181, 275-285
3.418Citations (PDF)
195Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells
Journal of Virology, 2015, 89, 97-109
3.643Citations (PDF)
196Anti-HIV Antibody–Dependent Activation of NK Cells Impairs NKp46 Expression
Journal of Immunology, 2014, 192, 308-315
0.640Citations (PDF)
197Modeling the Timing of Antilatency Drug Administration during HIV Treatment
Journal of Virology, 2014, 88, 14050-14056
3.621Citations (PDF)
198Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation
Aids, 2014, 28, 2781-2786
2.521Citations (PDF)
199Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity
Aids, 2014, 28, 1859-1870
2.537Citations (PDF)
200Toward Improved Influenza Vaccines
Journal of Infectious Diseases, 2014, 209, 4-5
3.82Citations (PDF)
201Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques
Journal of Virology, 2014, 88, 13418-13428
3.642Citations (PDF)
202The High Cost of Fidelity
AIDS Research and Human Retroviruses, 2014, 30, 8-16
1.440Citations (PDF)
203NKT cell depletion in humans during early HIV infection
Immunology and Cell Biology, 2014, 92, 578-590
2.634Citations (PDF)
204Linking Pig-Tailed Macaque Major Histocompatibility Complex Class I Haplotypes and Cytotoxic T Lymphocyte Escape Mutations in Simian Immunodeficiency Virus Infection
Journal of Virology, 2014, 88, 14310-14325
3.622Citations (PDF)
205HIV‐specific antibody‐dependent phagocytosis matures during HIV infection
Immunology and Cell Biology, 2014, 92, 679-687
2.630Citations (PDF)
206Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses
Journal of Infectious Diseases, 2014, 210, 1811-1822
3.867Citations (PDF)
207Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine
Journal of Immunology, 2014, 193, 469-475
0.6123Citations (PDF)
208The maturation of antibody technology for the HIV epidemic
Immunology and Cell Biology, 2014, 92, 570-577
2.66Citations (PDF)
209Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen
Journal of Virology, 2014, 88, 10412-10420
3.654Citations (PDF)
210Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy
European Journal of Clinical Microbiology and Infectious Diseases, 2014, 34, 253-259
2.60Citations (PDF)
211Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy
Journal of Infectious Diseases, 2014, 211, 529-538
3.828Citations (PDF)
212Measuring Turnover of SIV DNA in Resting CD4+ T Cells Using Pyrosequencing: Implications for the Timing of HIV Eradication Therapies
PLoS ONE, 2014, 9, e93330
2.311Citations (PDF)
213The role of T cell immunity in HIV-1 infection
Current Opinion in Virology, 2013, 3, 438-446
5.013Citations (PDF)
214Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques
Journal of Immunological Methods, 2013, 394, 73-83
1.423Citations (PDF)
215Characterisation of macaque testicular leucocyte populations and T-lymphocyte immunity
Journal of Reproductive Immunology, 2013, 100, 146-156
1.233Citations (PDF)
216In-vivostimulation of macaque natural killer T cells with α-galactosylceramide
Clinical and Experimental Immunology, 2013, 173, 480-492
3.416Citations (PDF)
217Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques
Journal of Virology, 2013, 87, 3760-3773
3.697Citations (PDF)
218Specific antibody‐dependent cellular cytotoxicity responses associated with slow progression of HIV infection
Immunology, 2013, 138, 116-123
4.7147Citations (PDF)
219Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses
Vaccine, 2013, 31, 5506-5517
3.119Citations (PDF)
220The search for an HIV cure: tackling latent infection
Lancet Infectious Diseases, The, 2013, 13, 614-621
16.564Citations (PDF)
221Mechanically Tunable, Self‐Adjuvanting Nanoengineered Polypeptide Particles
Advanced Materials, 2013, 25, 3468-3472
24.592Citations (PDF)
222Age-Associated Cross-reactive Antibody-Dependent Cellular Cytotoxicity Toward 2009 Pandemic Influenza A Virus Subtype H1N1
Journal of Infectious Diseases, 2013, 208, 1051-1061
3.863Citations (PDF)
223Characterization of the Kynurenine Pathway and Quinolinic Acid Production in Macaque Macrophages
International Journal of Tryptophan Research, 2013, 6,
3.728Citations (PDF)
224Trivalent Live Attenuated Influenza-Simian Immunodeficiency Virus Vaccines: Efficacy and Evolution of Cytotoxic T Lymphocyte Escape in Macaques
Journal of Virology, 2013, 87, 4146-4160
3.617Citations (PDF)
225Standard Trivalent Influenza Virus Protein Vaccination Does Not Prime Antibody-Dependent Cellular Cytotoxicity in Macaques
Journal of Virology, 2013, 87, 13706-13718
3.643Citations (PDF)
226Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques
Journal of Virology, 2013, 87, 5512-5522
3.6180Citations (PDF)
227Activation of NK cells by HIV-specific ADCC antibodies
Human Vaccines and Immunotherapeutics, 2013, 9, 1011-1018
3.115Citations (PDF)
228Short Communication: Antibody Responses to Human Immunodeficiency Virus Envelope from Infections with Multiple Subtypes Utilize the 1F7-Idiotypic Repertoire
AIDS Research and Human Retroviruses, 2013, 29, 778-783
1.44Citations (PDF)
229Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ human leukocyte antigen-B alleles in HIV controllers
Aids, 2013, 27, 519-528
2.544Citations (PDF)
230Induction of SerpinB2 and Th1/Th2 Modulation by SerpinB2 during Lentiviral Infections In Vivo
PLoS ONE, 2013, 8, e57343
2.318Citations (PDF)
231An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells
PLoS Pathogens, 2012, 8, e1002615
4.423Citations (PDF)
232Loss of Control of HIV Viremia Associated with the Fat Malabsorption Drug Orlistat
AIDS Research and Human Retroviruses, 2012, 28, 961-962
1.418Citations (PDF)
233Long-lived epithelial immunity by tissue-resident memory T (T RM ) cells in the absence of persisting local antigen presentation
Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7037-7042
7.5601Citations (PDF)
234HIV Infection Abrogates the Functional Advantage of Natural Killer Cells Educated through KIR3DL1/HLA-Bw4 Interactions To Mediate Anti-HIV Antibody-Dependent Cellular Cytotoxicity
Journal of Virology, 2012, 86, 4488-4495
3.651Citations (PDF)
235Anti‐HIV‐1 antibody‐dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG
European Journal of Immunology, 2012, 42, 2771-2781
3.224Citations (PDF)
236Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Journal of Immunological Methods, 2012, 384, 51-61
1.464Citations (PDF)
237HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality
Expert Review of Clinical Immunology, 2012, 8, 767-774
3.57Citations (PDF)
238Comparison of Influenza and SIV Specific CD8 T Cell Responses in Macaques
PLoS ONE, 2012, 7, e32431
2.310Citations (PDF)
239Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells
PLoS ONE, 2012, 7, e38580
2.323Citations (PDF)
240Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development
Advances in Virology, 2012, 2012, 1-8
1.820Citations (PDF)
241Ex-vivo α-Galactosylceramide activation of NKT cells in humans and macaques
Journal of Immunological Methods, 2012, 382, 150-159
1.421Citations (PDF)
242Characterisation of simian immunodeficiency virus-infected cells in pigtail macaques
Virology, 2012, 428, 11-20
2.34Citations (PDF)
243NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients
Viral Immunology, 2011, 24, 359-368
1.161Citations (PDF)
244Activation of NK Cells by ADCC Antibodies and HIV Disease Progression
Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 127-131
1.7118Citations (PDF)
245Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection
Virology, 2011, 412, 110-116
2.337Citations (PDF)
246Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques
Immunogenetics, 2011, 63, 511-521
2.830Citations (PDF)
247Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure
Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7505-7510
7.5138Citations (PDF)
248Replication-Competent Simian Immunodeficiency Virus (SIV) Gag Escape Mutations Archived in Latent Reservoirs during Antiretroviral Treatment of SIV-Infected Macaques
Journal of Virology, 2011, 85, 9167-9175
3.636Citations (PDF)
249Timing of Immune Escape Linked to Success or Failure of Vaccination
PLoS ONE, 2010, 5, e12774
2.313Citations (PDF)
250Does Cytolysis by CD8+ T Cells Drive Immune Escape in HIV Infection?
Journal of Immunology, 2010, 185, 5093-5101
0.631Citations (PDF)
251AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines
PLoS Medicine, 2010, 7, e1000331
8.112Citations (PDF)
252Evaluation of Recombinant Influenza Virus-Simian Immunodeficiency Virus Vaccines in Macaques
Journal of Virology, 2009, 83, 7619-7628
3.631Citations (PDF)
253Complexity of the Inoculum Determines the Rate of Reversion of SIV Gag CD8 T Cell Mutant Virus and Outcome of Infection
PLoS Pathogens, 2009, 5, e1000378
4.410Citations (PDF)
254Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy
Journal of Virology, 2009, 83, 1501-1510
3.615Citations (PDF)
255Substantial envelope-specific CD8 T-cell immunity fails to control siv disease
Virology, 2009, 384, 21-27
2.311Citations (PDF)
256Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques
Virology, 2009, 388, 315-323
2.310Citations (PDF)
257A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules
Biomaterials, 2009, 30, 5178-5186
12.1133Citations (PDF)
258Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens
Vaccine, 2009, 27, 6605-6612
3.138Citations (PDF)
259A Protective Vaccine Delivery System for In Vivo T Cell Stimulation Using Nanoengineered Polymer Hydrogel Capsules
ACS Nano, 2009, 3, 3391-3400
15.3177Citations (PDF)
260Thrombocytopenia Is Strongly Associated With Simian AIDS in Pigtail Macaques
Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 374-379
1.717Citations (PDF)
261Designing Immunity to Hiv: Manipulating Antibody-Dependent Cellular Cytotoxicity Antibodies
HIV Therapy, 2009, 3, 633-640
0.50Citations (PDF)
262Binding, Internalization, and Antigen Presentation of Vaccine‐Loaded Nanoengineered Capsules in Blood
Advanced Materials, 2008, 20, 4698-4703
24.5156Citations (PDF)
263HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression
Clinical and Experimental Immunology, 2008, 95, 450-454
3.47Citations (PDF)
264Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques
Virology, 2008, 374, 528-534
2.322Citations (PDF)
265Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques
Virology, 2008, 381, 11-15
2.312Citations (PDF)
266Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs
Journal of Medical Primatology, 2008, 37, 24-32
0.73Citations (PDF)
267Safety, immunogenicity and efficacy of peptide‐pulsed cellular immunotherapy in macaques
Journal of Medical Primatology, 2008, 37, 69-78
0.713Citations (PDF)
268Delivery of immunotherapy with peptide-pulsed blood in macaques
Virology, 2008, 378, 201-204
2.39Citations (PDF)
269Anti-SIV Cytolytic Molecules in Pigtail Macaques
AIDS Research and Human Retroviruses, 2008, 24, 1127-1131
1.40Citations (PDF)
270Quantification of Simian Immunodeficiency Virus Cytotoxic T Lymphocyte Escape Mutant Viruses
AIDS Research and Human Retroviruses, 2008, 24, 1067-1072
1.412Citations (PDF)
271Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood
PLoS Pathogens, 2008, 4, e1000055
4.447Citations (PDF)
272Vaccination and Timing Influence SIV Immune Escape Viral Dynamics In Vivo
PLoS Pathogens, 2008, 4, e12
4.444Citations (PDF)
273Natural Host Genetic Resistance to Lentiviral CNS Disease: A Neuroprotective MHC Class I Allele in SIV-Infected Macaques
PLoS ONE, 2008, 3, e3603
2.324Citations (PDF)
274Utility of Human Immunodeficiency Virus Type 1 Envelope as a T-Cell Immunogen
Journal of Virology, 2007, 81, 13125-13134
3.628Citations (PDF)
275Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques
Journal of Virology, 2007, 81, 292-300
3.648Citations (PDF)
276Vaccine-Induced T Cells Control Reversion of AIDS Virus Immune Escape Mutants
Journal of Virology, 2007, 81, 4137-4144
3.634Citations (PDF)
277Title is missing!
Retrovirology, 2007, 4, 7
3.542Citations (PDF)
278The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection
Hepatology, 2007, 46, 1332-1340
10.149Citations (PDF)
279Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials
Vaccine, 2006, 24, 1378-1388
3.142Citations (PDF)
280A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1
Aids, 2006, 20, 294-297
2.558Citations (PDF)
281MHC class I allele frequencies in pigtail macaques of diverse origin
Immunogenetics, 2006, 58, 995-1001
2.838Citations (PDF)
282Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials
Hum Vaccin, 2006, 2, 134-136
2.813Citations (PDF)
283Comparative Evaluation of Simian, Simian–Human, and Human Immunodeficiency Virus Infections in the Pigtail Macaque (Macaca nemestrina) Model
AIDS Research and Human Retroviruses, 2006, 22, 580-588
1.467Citations (PDF)
284CD127 + CCR5 + CD38 +++ CD4 + Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2 + Memory CD4 + T Cells
Journal of Virology, 2006, 80, 10151-10161
3.650Citations (PDF)
285Short Communication: Characteristics of Effective Immune Control of Simian/Human Immunodeficiency Virus in Pigtail Macaques
AIDS Research and Human Retroviruses, 2006, 22, 27-32
1.41Citations (PDF)
286The pigtail macaque MHC class I alleleMane-A*10presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion
Journal of Medical Primatology, 2005, 34, 282-293
0.747Citations (PDF)
287Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: Analysis and strategies to ameliorate
Journal of Immunological Methods, 2005, 297, 177-186
1.415Citations (PDF)
288Phenotypic and kinetic analysis of effective simian–human immunodeficiency virus-specific T cell responses in DNA- and fowlpox virus-vaccinated macaques
Virology, 2005, 337, 222-234
2.32Citations (PDF)
289Enhanced Cellular Immunity in Macaques following a Novel Peptide Immunotherapy
Journal of Virology, 2005, 79, 3748-3757
3.630Citations (PDF)
290Comparison of Whole Gene and Whole Virus Scrambled Antigen Approaches for DNA Prime and Fowlpox Virus Boost HIV Type 1 Vaccine Regimens in Macaques
AIDS Research and Human Retroviruses, 2005, 21, 292-300
1.48Citations (PDF)
291Analysis of Pigtail Macaque Major Histocompatibility Complex Class I Molecules Presenting Immunodominant Simian Immunodeficiency Virus Epitopes
Journal of Virology, 2005, 79, 684-695
3.672Citations (PDF)
292Reduced Hepatitis B Virus (HBV)-Specific CD4 + T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy
Journal of Virology, 2005, 79, 3038-3051
3.679Citations (PDF)
293Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity
Trends in Microbiology, 2005, 13, 243-246
8.241Citations (PDF)
294Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques
Vaccine, 2005, 23, 1949-1956
3.129Citations (PDF)
295Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use
Vaccine, 2005, 23, 4647-4657
3.136Citations (PDF)
296Mucosally-administered human–simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3
Vaccine, 2005, 23, 5009-5021
3.160Citations (PDF)
297Genetic influences on HIV infection: implications for vaccine development
Sexual Health, 2005, 2, 53
1.77Citations (PDF)
298Efficacy of DNA and Fowlpox Virus Priming/Boosting Vaccines for Simian/Human Immunodeficiency Virus
Journal of Virology, 2004, 78, 13819-13828
3.678Citations (PDF)
299Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12
Vaccine, 2004, 23, 188-197
3.147Citations (PDF)
300Decreased Neurotropism of nef Long Terminal Repeat ( nef /LTR)-Deleted Simian Immunodeficiency Virus
Journal of NeuroVirology, 2003, 9, 442-451
1.618Citations (PDF)
301Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma
Journal of Medical Primatology, 2003, 29, 240-247
0.721Citations (PDF)
302Lipopolysaccharide induces biochemical alterations in chicks trained on the passive avoidance learning task
Physiology and Behavior, 2003, 78, 679-688
2.212Citations (PDF)
303Decreased Neurotropism of nef Long Terminal Repeat ( nef /LTR)-Deleted Simian Immunodeficiency Virus
Journal of NeuroVirology, 2003, 9, 442-451
1.60Citations (PDF)
304Evidence of Recombination between 3′ and 5′ LTRs in Macaques Inoculated with SIV DNA
AIDS Research and Human Retroviruses, 2002, 18, 227-230
1.411Citations (PDF)
305Vaccines for HIV in the developing world
Internal Medicine Journal, 2002, 32, 136-137
0.80Citations (PDF)
306Chimeric Human Papilloma Virus–Simian/Human Immunodeficiency Virus Virus-like-Particle Vaccines: Immunogenicity and Protective Efficacy in Macaques
Virology, 2002, 301, 176-187
2.364Citations (PDF)
307Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques
Immunological Reviews, 2001, 183, 94-108
6.58Citations (PDF)
308Attenuated and Wild-Type HIV-1 Infections and Long Terminal Repeat-Mediated Gene Expression from Plasmids Delivered by Gene Gun to Human Skin ex Vivo and Macaques in Vivo
Virology, 2001, 287, 71-78
2.39Citations (PDF)
309Nucleic Acid Vaccines Tasks and Tactics
Immunologic Research, 2001, 24, 225-244
2.813Citations (PDF)
310Simian immunodeficiency virus infections in vervet monkeys (Clorocebus aethiops) at an Australian zoo
Australian Veterinary Journal, 2001, 79, 406-408
1.41Citations (PDF)
311Vaccination with Attenuated Simian Immunodeficiency Virus by DNA Inoculation
Journal of Virology, 2001, 75, 11930-11934
3.632Citations (PDF)
312Vaccines for HIV
Expert Opinion on Therapeutic Patents, 2000, 10, 1179-1188
3.94Citations (PDF)
313A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques
Vaccine, 2000, 18, 2250-2256
3.138Citations (PDF)
314Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
Immunological Reviews, 1999, 171, 27-44
6.589Citations (PDF)
315A Minimally Replicative HIV-2 Live-Virus Vaccine ProtectsM. nemestrinafrom Disease after HIV-2287Challenge
Virology, 1998, 242, 150-160
2.337Citations (PDF)
316Preventive HIV-1 vaccines: where are we going?
International Journal of STD and AIDS, 1998, 9, 715-719
1.22Citations (PDF)
317Reply
Journal of Infectious Diseases, 1998, 177, 1771-1772
3.81Citations (PDF)
318Human Immunodeficiency Virus Type 1 (HIV‐1)‐Specific T Cell Responses Correlate with Control of Acute HIV‐1 Infection in Macaques
Journal of Infectious Diseases, 1997, 176, 1188-1197
3.849Citations (PDF)
319Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection
Aids, 1997, 11, 1565-1574
2.579Citations (PDF)
3208.3 Prospects for a preventive HIV vaccine
Medical Journal of Australia, 1996, 165, 212-215
1.72Citations (PDF)
321Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina.
Journal of Clinical Investigation, 1995, 95, 248-256
10.629Citations (PDF)
322Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses
AIDS Research and Human Retroviruses, 1994, 10, 551-560
1.418Citations (PDF)
323Listeria monocytogenes peritonitis with review of literature
Australian and New Zealand Journal of Medicine, 1994, 24, 405-405
0.41Citations (PDF)
324HIV Infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans
Journal of Leukocyte Biology, 1994, 56, 318-327
2.966Citations (PDF)
325Tuberculous Meningitis: A 30-Year Review
Clinical Infectious Diseases, 1993, 17, 987-994
5.2252Citations (PDF)
326Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis
Aids, 1992, 6, 1169-1174
2.537Citations (PDF)
327Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria
ELife, 0, 10,
1.636Citations (PDF)
328Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial
Journal of Infectious Diseases, 0, 232, 1319-1329
3.80Citations (PDF)
329HLA-B*15:01-positive severe COVID-19 patients lack CD8 <sup>+</sup> T cell pools with highly expanded public clonotypes
Proceedings of the National Academy of Sciences of the United States of America, 0, 122,
7.50Citations (PDF)
330Altered Corneal T-Cell Motility and Sensory Nerve Features in Older Adults With Human Immunodeficiency Virus Infection
0, 66, 23
0Citations (PDF)
331Influence of hydrophilic polymers on the accelerated blood clearance of mRNA lipid nanoparticles upon repeated administration
Nanoscale Horizons, 0, 10, 3396-3404
6.51Citations (PDF)
332PEG-free Lipid Nanoparticles for mRNA Delivery: Superhydrophilic Sulfoxide Polymer Coatings
Biomacromolecules, 0, 27, 624-639
5.10Citations (PDF)
333Low‐level human memory T and B cells recognising avian influenza hemagglutinins are poorly responsive to existing seasonal influenza vaccines
Clinical and Translational Immunology, 0, 14,
3.60Citations (PDF)